Nonpsychotropic cannabinoid receptors regulate microglial cell migration

Journal of Neuroscience

Volumn 23, Issue 4, 2003, Pages 1398-1405

  Walter, Lisa ^a   Franklin, Allyn ^a   Witting, Anke ^a   Wade, Christian ^a   Xie, Yiheng ^b   Kunos, George ^c   Mackie, Ken ^b   Stella, Nephi ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Cannabinoids; Glutamate; Kinase; Microglia; Migration; Purinergic

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADENOSINE TRIPHOSPHATE; ANANDAMIDE; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOL; CARBACHOL; DOCOSATETRAENYLETHANOLAMIDE; GLUTAMIC ACID; HOMO GAMMA LINOLENYLETHANOLAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL DAMAGE; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; IMMUNOCYTOCHEMISTRY; INFLAMMATION; LAMELLIPODIUM; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 0037442829     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-04-01398.2003     Document Type: Article

References (74)

1. Baker D, Pryce G, Croxford LJ, Brown P, Pertwee RG, Huffman JW, Layward L (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84-87.
2. Baker D, Pryce G, Croxford LJ, Brown P, Pertwee RG, Makriyannis A, Knanolkar A, Layward L, Fezza F, Bisogno T, DiMarzo V (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300-302.
3. Becher B, Antel JP (1996) Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia. Glia 18:1-10.
4. Becher B, Prat A, Antel JP (2000) Brain-immune connection: immunoregulatory properties of CNS-resident cells. Glia 29:293-304.
5. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Matzo V (1997) Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 322:671-677.
6. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrié B, Rinaldi-Carmona M, Calandra B, Le Fur G, Casellas P (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Eur J Biochem 237:704-711.
7. Bouaboula M, Dussossoy D, Casellas P (1999) Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR144528. J Biol Chem 274:20397-20405.
8. Bruce-Keller AJ (1999) Microglial-neuronal interactions in synaptic damage and recovery. J Neurosci Res 58:191-201.
9. Buckley NE, McCoy KI., Mezey E, Bonner T, Zimmer A, Felder CC, Glass M, Zimmer A (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur J Pharmacol 396:141-149.
10. 2+-induced relaxation in CB1 receptor-deficient mice. Hypotension 39:251-257.
11. Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38:44-48.
12. Derocq J-M, Ibilo O, Bouaboula M, Ségui M, Clére C, Casellas P (2000) Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. J Biol Chem 275:15621-15628.
13. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
14. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J-C, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691.
15. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 90:7656-7660.
16. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
17. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signalling in dorsal striatum. Nat Neurosci 2:358-363.
18. Goutopoulos A, Fan P, Khanolkar AD, Xie X-Q, Lin S, Makriyannis A (2001) Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg Med Chem 9:1673-1684.
19. Griffin G, Tao Q, Abood ME (2000) Cloning and pharmacological characterization of the rat CB2 cannabinoid receptor. J Pharmacol Exp Ther 292:886-894.
20. Hájos N, Katona I, Naiem SS, Mackie K, Ledent C, Mody I, Freund TF (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12:3239-3249.
21. Hall W, Solowij N (1998) Adverse effects of cannabis. Lancet 352:1611-1616.
22. Hampson RE, Deadwyler SA (2000) Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats. J Neurosci 20:8932-8942.
23. Hanus L, Gopher A, Almog S, Mechoulam R (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36:3032-3034.
24. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662-3665.
25. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
26. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58:322-328.
27. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96:14136-14141.
28. Jung M, Calassi R, Rinaldi-Carmona M, Chardenot P, Le Fur G, Soubrié P, Oury-Donat F (1997) Characterization of CB1 receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A. J Neurochem 68:402-409.
29. Kaminski NE (1998) Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. J Neuroimmunol 83:124-132.
30. Kim M, Spelta V, Sim J, North AR, Surprenant A (2001) Differential assembly of rat purinergic P2X7 receptor in immune cells of the brain and periphery. J Biol Chem 276:23262-23267.
31. Klein TW, Friedman H, Specter S (1998) Marijuana, immunity and infection. J Neuroimmunol 83:102-115.
32. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA (1997) Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 137:481-492.
33. Kreitzer AC, Regehr WG (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717-727.
34. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312-318.
35. Lee SF, Newton C, Widen R, Friedman H, Klein TW (2001) Differential expression of cannabinoid CB2 receptor mRNA in mouse immune cell subpopulation and following B cell stimulation. Eur J Pharmacol 423:235-241.
36. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB (1989) Δ9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23:73-81.
37. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in routine collagen-induced arthritis. Proc Natl Acad Sci USA 97:9361-9566.
38. 9-tetrahydrocannabinol or anandamide. Psychopharmacology 140:11-19.
39. Martyn CN, Illis LS, Thom J (1995) Nabilone in the treatment of multiple sclerosis. Lancet 345:579.
40. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
41. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90.
42. Meinck H-M, Schönle PW, Conrad B (1989) Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 236:120-122.
43. Mitchison TJ, Cramer LP (1996) Actin-based cell motility and cell locomotion. Cell 84:371-379.
44. Möller T, Kann O, Verkhratsky A, Kettenmann H (2000) Activation of mouse microglial cells affects P2 receptor signaling. Brain Res 853:49-59.
45. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
46. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527-531.
47. 9-tetrahydrocannabinol, cannabinol, and cannabidiol. Experientia (Basel) 29:1368-1369.
48. Pertwee R, Griffen G, Hanus L, Mechoulam R (1994) Effects of two fatty acid ethanoloamides on mouse vasa deferentia. Eur J Pharmacol 259:115-120.
49. Piomelli D, Beltramo M, Giuffrida A, Stella N (1998) Endogenous cannabinoid signaling. Neurobiol Dis 5:462-473.
50. Rezaie P, Male D (1999) Colonisation of the developing human brain and spinal cord by microglia: a review. Microscopy Res Tech 45:359-382.
51. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Breliére JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
52. Rinaldi-Carmona M, Barth F, Millan J, Derocq J-M, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Breliere J-C, Le Fur G (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
53. Rodríguez JJ, Mackie K, Pickel VM (2001) Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 21:823-833.
54. Schmid PC, Schwartz KD, Smith CN, Krebsbach RJ, Berdyshev EV, Schmid HHO (2000) A sensitive endocannabinoid assay: the simultaneous analysis of N-acylethanolamines and 2-monoacylglycerols. Chem Phys Lipids 104:185-191.
55. Schwartzfarb I., Needle M, Chavez-Chase M (1974) Dose-related inhibition of leukocyte migration by marijuana and delta-9-tetrahydrocannabinol (THC) in vitro. J Clin Pharmacol 1:35-41.
56. Servant G, Weiner OD, Neptune ER, Sedat JW, Bourne HR (1999) Dynamics of a chemoattractant receptor in living neutrophils during chemotaxis. Mol Biol Cell 10:1163-1178.
57. Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989-999.
58. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287:1123-1131.
59. Stella N, Piomelli D (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 425:189-196.
60. Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773-778.
61. Stence N, Waite M, Dailey ME (2001) Dynamics of microglial activation. Glia 33:256-266.
62. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97.
63. Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K (2000) Evidence that 2-arachidonylglycerol but not N-palmitpylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. J Biol Chem 275:605-612.
64. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411.
65. Wade CB, Robinson S, Shapiro R, Dorsa DM (2001) Estrogen receptor (ER)a and ERb exhibit unique pharmacological properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology 142:2336-2342.
66. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G (1997) Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390:518-521.
67. Waksman Y, Olson JM, Carlisle SJ, Cabral GY (1999) The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 288:1357-1366.
68. Walter L, Franklin A, Witting A, Möller T, Stella N (2002) Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem 277:20869-20876.
69. Watanabe N, Mitchison TJ (2002) Single-molecule speckle analysis of actine filament turnover in lamellipodia. Science 295:1083-1087.
70. Watson SJ, Benson JA, Joy JE (2000) Marijuana and medicine: assessing the science base. Arch Gen Psychiatry 57:547-552.
71. Wilkinson PC (1998) Assays of leucocyte locomotion and chemotaxis. J Immunol Methods 216:139-153.
72. Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588-592.
73. Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T (1994) Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28:209-214.
74. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5785.